Antihypertensives do not impair survival in atezolizumab-treated cancer patients
Concomitant use of antihypertensive medications, including renin–angiotensin system inhibitor (RASi), does not appear to affect survival and immune-related safety outcomes during atezolizumab therapy in patients with solid cancers, results of a study have shown.